^
    2d
    LYMFOR: [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma (clinicaltrials.gov)
    P3, N=148, Not yet recruiting, Pentixapharm AG | Initiation date: Dec 2023 --> May 2024
    Trial initiation date • FDG PET
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CXCR4 expression • CXCR4 positive
    3d
    Paediatric cutaneous lymphomas including rare subtypes: A 40-year experience at a tertiary referral centre. (PubMed, J Eur Acad Dermatol Venereol)
    Our findings shed light on the peculiar aspects and long-term outcomes of paediatric cutaneous lymphomas, particularly emphasizing their distinctive features in comparison to their adult counterparts and exploring the less common subtypes. Further larger-scale studies are warranted to better characterize these entities and to achieve a more rapid and accurate diagnosis.
    Journal
    |
    CD4 (CD4 Molecule)
    4d
    ACE-LY-003: Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Acerta Pharma BV | Phase classification: P1 --> P1/2
    Phase classification • Combination therapy
    |
    Rituxan (rituximab) • lenalidomide • Calquence (acalabrutinib)
    4d
    17P.176: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (clinicaltrials.gov)
    P2, N=30, Recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    5d
    MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases. (PubMed, Diagn Pathol)
    MNDA was highly expressed in MZL with a potential utility in differential diagnosis between MZL and RLH as well as FL, whereas its value in distinguishing MZL from MCL, CLL/SLL is limited. In addition, MNDA expression in DLBCL was more frequently seen in the non-GCB group and the BCL2/MYC double-expression group, and demonstrated a correlation with CD5, which deserves further investigation. The clinical relevance of MNDA and its correlation with the prognosis of these lymphomas also warrant to be fully elucidated.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule)
    |
    BCL2 expression • MYC expression
    8d
    Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. (PubMed, EClinicalMedicine)
    MZL-IPI is a new prognostic score for use in all patients with MZL considered for systemic treatment. The MER was supported by P50 CA97274 and U01 CA195568.
    Journal
    |
    CA9 (Carbonic anhydrase 9)
    8d
    A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) (clinicaltrials.gov)
    P2, N=111, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Yinuokai (orelabrutinib)
    9d
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=422, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Onureg (azacitidine oral) • Mabtas (rituximab biosimilar)
    13d
    Covalent docking-driven virtual screening of extensive small-molecule libraries against Bruton tyrosine kinase for the identification of highly selective and potent novel therapeutic candidates. (PubMed, J Mol Graph Model)
    The covalently bound Ibrutinib molecule, recognized for its ability to inhibit BTK, was used as the query molecule...Covalent docking simulations were applied to the selected small-molecules obtained through text mining from databases. Potent hit molecules capable of inhibiting BTKs through virtual screening algorithms were identified, paving the way for novel therapeutic strategies in the treatment of CLL.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Imbruvica (ibrutinib)
    14d
    Endoscopic ultrasound-guided fine needle biopsy diagnosis of circumferentially extraluminal mucosa-associated lymphoid tissue lymphoma in the transverse colon: a case report. (PubMed, Clin J Gastroenterol)
    We performed bendamustine-rituximab (BR)-combined therapy. After six courses of BR-combined therapy, colonoscopy revealed improvement in the lead pipe sign and CT revealed disappearance of the mass.
    Journal • Biopsy
    |
    CD20 (Membrane Spanning 4-Domains A1) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • MALT1 (MALT1 Paracaspase)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine
    15d
    Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of Washington | Trial completion date: Aug 2028 --> Aug 2029 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    Opdivo (nivolumab)
    16d
    GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov)
    P1, N=78, Recruiting, Adicet Bio, Inc | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • ADI-001
    16d
    Blood MALT1 expression could help predict treatment outcomes in psoriasis patients, especially in those receiving biologics. (PubMed, Immun Inflamm Dis)
    Blood MALT1 measurement may assist in predicting outcomes in psoriasis patients, especially in those receiving biologics.
    Journal
    |
    MALT1 (MALT1 Paracaspase)
    |
    MALT1 expression
    17d
    Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Beth Christian | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab)
    20d
    Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group. (PubMed, J Eur Acad Dermatol Venereol)
    The 5th WHO classification further introduces and provides essential and desirable diagnostic criteria for each disease type and includes chapters on reactive B- or T-cell rich lymphoid proliferations formerly referred as cutaneous pseudolymphomas, as well as histiocyte and CD8 T-cell rich LPD in patients with inborn error of immunity. As already emphasized in previous lymphoma classifications, the importance of integrating clinical, histological, phenotypic and molecular features remains the crucial conceptual base for defining cutaneous (and extracutaneous) lymphomas.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    21d
    Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas (clinicaltrials.gov)
    P2, N=43, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial
    |
    Brukinsa (zanubrutinib) • Rituxan Hycela (rituximab/hyaluronidase)
    22d
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    P-CD19CD20-ALLO1 • rimiducid (AP1903)
    22d
    BGB-16673-101: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=466, Recruiting, BeiGene | N=291 --> 466
    Enrollment change
    |
    BGB-16673
    23d
    AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (clinicaltrials.gov)
    P1, N=120, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD22 (CD22 Molecule)
    25d
    AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Stanford University
    New P1 trial • CAR T-Cell Therapy
    |
    CD22 (CD22 Molecule)
    26d
    Tertiary lymphoid organs in wild boar exposed to a low-virulent isolate of African swine fever virus. (PubMed, Vet Q)
    However, the structural similarities between TLOs and MALTs and the location of TLOs close to the mucosa suggest that they may perform a similar function, facilitating a local protective response. Nevertheless, further investigations are warranted to assess the cellular and humoral dynamics of these lymphoid organs induced by attenuated isolates.
    Journal
    |
    PAX5 (Paired Box 5) • LYVE1 (Lymphatic vessel endothelial hyaluronan receptor 1)
    29d
    Inhibition of the MALT1-LPCAT3 axis protects cartilage degeneration and osteoarthritis. (PubMed, Cell Commun Signal)
    Overall, our data reveal a previously unrecognized role of the MALT1-LPCAT3 axis in osteoarthritis. Targeting the MALT1-LPCAT3 pathway with MALT1 inhibitors or siRNA-liposomes of LPCAT3 may become an effective strategy to treat OA by suppressing eicosanoids, matrix-degrading enzymes, and proinflammatory cytokines.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MALT1 (MALT1 Paracaspase) • IL1B (Interleukin 1, beta) • LPCAT3 (Lysophosphatidylcholine Acyltransferase 3) • MMP3 (Matrix metallopeptidase 3)
    |
    MYC expression • MALT1 expression • MALT1 overexpression
    30d
    Nodal Low-Grade B-Cell Lymphoma Co-Expressing CD5 and CD10 but Not CD23, IRTA1, or Cyclin D1: The Diagnostic Challenge of a Splenic Marginal Zone Lymphoma. (PubMed, Diagnostics (Basel))
    The dual expression of CD5 and CD10 is extremely unusual for low-grade BCL and may lead to an erroneous diagnosis. Integrating the findings into peripheral blood smear tests, flow cytometry, histopathology, imaging, and clinical features is mandatory to exclude other lymphoma types and to reach a correct diagnosis, particularly for a case with nodal presentation.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CCND1 expression
    30d
    Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview. (PubMed, Hematol Rep)
    Treatment approaches are evolving, with chemoimmunotherapy remaining standard for many indolent cases while intensified regimens and targeted agents show promise for refractory or high-risk aggressive disease. Continued elucidation of the genetic and microenvironmental underpinnings of lymphomagenesis is critical for developing personalized therapeutic strategies.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC translocation
    1m
    EPCORE NHL-1: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=666, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | Trial completion date: Apr 2029 --> Jan 2029
    Enrollment closed • Trial completion date
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp)
    1m
    BRUIN: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1/2, N=860, Active, not recruiting, Loxo Oncology, Inc. | Trial completion date: Apr 2024 --> Jan 2028 | Trial primary completion date: Apr 2024 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
    1m
    Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Novartis Pharmaceuticals | N=124 --> 40 | Trial completion date: Jun 2027 --> Oct 2026 | Trial primary completion date: Jun 2027 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    lenalidomide • ianalumab (VAY736)
    1m
    NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=42, Recruiting, University of Washington | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    1m
    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV
    1m
    Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=69, Recruiting, Barbara Ann Karmanos Cancer Institute | Phase classification: P1b/2 --> P1/2 | N=44 --> 69 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Rituxan (rituximab) • Xpovio (selinexor)
    1m
    Cutaneous lymphoproliferative disorders: Back to the future. (PubMed, J Cutan Pathol)
    While the 2022 ICC introduced the term "primary cutaneous marginal zone LPD," in the 5th edition of the WHO classification PCMZL is maintained. In this review we describe the background and rationale of the continually changing terminology of these conditions and discuss the clinical consequences of downgrading malignant lymphomas to LPDs.
    Review • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    1m
    Gastric metastasis from breast cancer: five cases and a single-institutional review. (PubMed, J Int Med Res)
    In conclusion, the gastric metastasis of breast cancer incidence rate is low, and misdiagnosis can lead to insufficient or excessive treatment. Multiple biopsies and immunohistochemistry should be performed to diagnose gastric metastasis of breast cancer.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • GATA3 (GATA binding protein 3) • SCGB2A2 (Secretoglobin Family 2A Member 2)
    |
    HER-2 negative
    1m
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Enterome | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    1m
    A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, BeiGene
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447
    1m
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (clinicaltrials.gov)
    P=N/A, N=50000, Recruiting, Massive Bio, Inc. | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • CLDN18 (Claudin 18) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • NRG1 (Neuregulin 1) • POLE (DNA Polymerase Epsilon) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VEGFA (Vascular endothelial growth factor A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PTCH1 (Patched 1) • FGFR4 (Fibroblast growth factor receptor 4) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • TSC2 (TSC complex subunit 2) • CHEK2 (Checkpoint kinase 2) • PD-L2 (Programmed Cell Death 1 Ligand 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • JAK1 (Janus Kinase 1) • FANCA (FA Complementation Group A) • TSC1 (TSC complex subunit 1) • MDM4 (The mouse double minute 4) • POLD1 (DNA Polymerase Delta 1) • CDK6 (Cyclin-dependent kinase 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • AURKA (Aurora kinase A) • JAK3 (Janus Kinase 3) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • CHEK1 (Checkpoint kinase 1) • GATA6 (GATA Binding Protein 6) • MSH3 (MutS Homolog 3) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • GNAS (GNAS Complex Locus) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3) • CSF1R (Colony stimulating factor 1 receptor) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • HDAC1 (Histone Deacetylase 1) • PRDM1 (PR/SET Domain 1) • ZNF217 (Zinc Finger Protein 217) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GATA3 (GATA binding protein 3) • PARP2 (Poly(ADP-Ribose) Polymerase 2) • PARP3 (Poly(ADP-Ribose) Polymerase Family Member 3) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • ACVR1B (Activin A Receptor Type 1B) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
    1m
    Histological criteria for selecting patients who need clonality test for non-gastric MALT lymphoma diagnosis. (PubMed, Diagn Pathol)
    Combining the width cutoff of 1.5 and the areal cutoff of 3.5, the sensitivity, specificity, positive predictive value, and negative predictive value for MALT lymphoma were 96.97%, 70.37%, 80.00%, and 95.00%, respectively. In conclusion, through objective measurement of the marginal zone, suspected cases of MALT lymphoma requiring a molecular clonality test can be effectively selected.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    1m
    MAHOGANY: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (clinicaltrials.gov)
    P3, N=750, Recruiting, BeiGene | Trial completion date: Jun 2029 --> Jun 2030
    Trial completion date
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    1m
    BELLWAVE-001: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (clinicaltrials.gov)
    P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BTK mutation • BCL6 translocation • BTK C481
    |
    nemtabrutinib (MK-1026)
    2ms
    Circulating tumor DNA and nivolumab maintenance: A pilot study in diffuse large B cell lymphoma (AACR 2024)
    Due to small sample size and lower than expected relapse, we were unable to demonstrate conversion of dMRD to uMRD using MN. However, this pilot study did confirm high correlation of uMRD and dMRD status with disease free survival and clinical relapse within 4 months, respectively. If strong negative predictive value is confirmed in a larger study, ctDNA MRD testing may be used to spare pts from imaging or to guide additional work up in pts with inconclusive findings on scans.
    Clinical • Circulating tumor DNA
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC translocation
    |
    clonoSEQ
    |
    Opdivo (nivolumab)
    2ms
    Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection. (PubMed, Br J Haematol)
    Cluster analysis by LymphGen classified 29/54 cases within definite groups, including BN2 in 14 (48.2%), ST2 in seven (24.2%) and MCD and EZB in four each (13.8%). Overall, these results indicate a preferential marginal zone origin for a consistent subgroup of HCV-associated DLBCL cases and suggest potential implications for molecularly targeted therapies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • PIM1 (Pim-1 Proto-Oncogene) • SETD1B (SET Domain Containing 1B, Histone Lysine Methyltransferase) • TBL1XR1 (TBL1X Receptor 1)
    |
    NOTCH mutation
    2ms
    17P.176: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (clinicaltrials.gov)
    P2, N=30, Recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial completion date: Dec 2023 --> Feb 2031
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    2ms
    Long-term monitoring of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene. (PubMed, Sci Rep)
    In conclusion, the presence of extra copies of MALT1 was identified as an inferior prognostic determinant of event-free survival. Consequently, trisomy/tetrasomy 18 may serve as an indicator of progression and refractoriness to therapeutic intervention in patients with gastric MALT lymphoma, particularly stage IV gastric MALT lymphoma.
    Journal
    |
    MALT1 (MALT1 Paracaspase)